An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer

Teschendorff, Andrew E.; Miremadi, Ahmad; Pinder, Sarah; Ellis, Ian O.; Caldas, Carlos

doi:10.1186/gb-2007-8-8-r157

Cited by 447 publications

(443 citation statements)

References 52 publications

(91 reference statements)

Supporting

Mentioning

400

Contrasting

Order By: Relevance

“…For ER-negative breast cancer, the expression levels of complement and immune response pathway genes have instead been shown to be more important for clinical outcome. 25 Even though our patient material is not equivalent to the patient material in the above-mentioned studies, it nevertheless suggests that a division of ER-positive disease can be achieved by merely analyzing one marker of proliferation, in line with another recent publication on Ki67. 22 Histological grade was not an independent prognostic factor in this study, not even in the subgroup of medically untreated patients, in which Ki67 was of independent prognostic value.…”

Section: Discussionmentioning

confidence: 70%

The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer

et al. 2010

View full text Add to dashboard Cite

The aim of this study was to evaluate the prognostic value of Ki67 in relation to established prognostic factors in lymph node-negative breast cancer, and furthermore, whether the prognostic impact was dependent on estrogen receptor (ER) status and histological grade. In 200 premenopausal patients, with 5 years of follow-up, Ki67 was determined on tissue microarrays. In univariate analysis, Ki67 (r20 vs 420%) was a prognostic factor for distant disease-free survival (hazard ratio: 2.7, 95% confidence interval: 1.3-5.4, P ¼ 0.005) and overall survival (hazard ratio: 4.9, 95% confidence interval: 1.7-14, P ¼ 0.003). When stratifying for ER status and histological grade, Ki67 was a significant prognostic factor for distant disease-free survival and overall survival only in the ER-positive group, and only in patients with histological grade 2, respectively. In multivariate analysis, human epidermal growth factor receptor 2 and age were independent prognostic factors for distant disease-free survival, whereas Ki67, histological grade, and tumor size were not. Ki67 was, however, an independent prognostic factor in the 87% of the patients who had not received adjuvant medical treatment. Agreement between the three readers was very good (j-values: 0.83-0.88). Furthermore, Ki67 was a significant prognostic factor for all three investigators (hazard ratio: 2.7-3.2). This study shows that Ki67 is a prognostic factor in node-negative breast cancer. It is noteworthy that the prognostic information of Ki67 is restricted to ER-positive patients, and to patients with histological grade 2. Taken together, Ki67, as an easily assessed and reproducible proliferation factor, may be an alternative or complement to histological grade as a prognostic tool and for selection of adjuvant treatment.

show abstract

Section: Discussionmentioning

confidence: 70%

The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Recently, several groups have identified a subgroup of good prognosis ERÀ cancers, encompassing a subgroup of triple-negative and basal-like tumors, which is characterized by the expression of an immune response module. [125][126][127][128] This transcriptomic profile may prove helpful for the identification of patients with triple-negative and basal-like cancers that have a better outcome. In this context, the finding of higher expression of CT-X antigens (in particular MAGE and NY-ESO) in this subgroup opens up another potential avenue for therapy as vaccines against these antigens are already in clinical trial for lung cancer.…”

Section: Clinical Behavior Of Basal-like and Triple-negative Breast Cmentioning

confidence: 99%

Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists

et al. 2011

Self Cite

View full text Add to dashboard Cite

Breast cancer is a heterogeneous disease encompassing a variety of entities with distinct morphological features and clinical behaviors. Although morphology is often associated with the pattern of molecular aberrations in breast cancers, it is also clear that tumors of the same histological type show remarkably different clinical behavior. This is particularly true for 'basal-like cancer', which is an entity defined using gene expression analysis. The purpose of this article was to review the current state of knowledge of basal-like breast cancers, to discuss the relationship between basal-like and triple-negative breast cancers, and to clarify practical implications of these diagnoses for pathologists and oncologists.

show abstract

“…Breast cancer is not a single disease [38]: breast cancer prognosis varies with expression of key hormone receptors: estrogen receptor (ER), progesterone receptor (PR) and her2/neu/ ERbB2 (Her2) [56] histologic grade [57], and presence of metastasis. Recent evidence suggests that the microenvironment in these tumors is different [58,59].…”

Section: Breast Cancer Subtypesmentioning

confidence: 99%

The extracellular matrix in breast cancer predicts prognosis through composition, splicing, and crosslinking

Robertson

2016

Experimental Cell Research

View full text Add to dashboard Cite

The extracellular matrix in breast cancer predicts prognosis through composition, splicing, and crosslinking a b s t r a c tThe extracellular matrix in the healthy breast has an important tumor suppressive role, whereas the abnormal ECM in tumors can promote aggressiveness, and has been linked to breast cancer relapse, survival and resistance to chemotherapy. This review article gives an overview of the elements of the ECM which have been linked to prognosis of breast cancers, including changes in ECM protein composition, splicing, and microstructure. Published by Elsevier Inc.

show abstract

An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer

Abstract: A feature selection method was used in an analysis of three major microarray expression datasets to identify molecular subclasses and prognostic markers in estrogen receptor-negative breast cancer, showing that it is a heterogeneous disease with at least four main subtypes.

Cited by 447 publications

References 52 publications

The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer

The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer

Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists

The extracellular matrix in breast cancer predicts prognosis through composition, splicing, and crosslinking

Contact Info

Product

Resources

About